The perplexity of prescribing and switching of biologic drugs in rheumatoid arthritis: a UK regional audit of practice by unknown
Blake et al. BMC Musculoskeletal Disorders 2014, 15:290
http://www.biomedcentral.com/1471-2474/15/290RESEARCH ARTICLE Open AccessThe perplexity of prescribing and switching of
biologic drugs in rheumatoid arthritis: a UK
regional audit of practice
Tim Blake1*, Vijay Rao2, Tahir Hashmi2, Nicola Erb3, Sheila Catherine O’Reilly4, Shireen Shaffu5,
Karen Obrenovic6 and Jon Packham1Abstract
Background: Biologic drugs are expensive treatments used in rheumatoid arthritis (RA). Switching among them is
common practice in patients who have had an inadequate response or intolerable adverse events. The National
Institute of Health and Clinical Excellence (NICE) UK, which aims to curtail postcode prescribing, has provided
guidance on the sequential prescription of these drugs. This study sought to evaluate the extent to which
rheumatology centres across the Midlands were complying with NICE guidance on the switching of biologic drugs
in RA, as well as analyse the various prescribing patterns of these drugs.
Methods: Data was collected via a web-based tool on RA patients who had undergone at least one switch of a
biologic drug during 2011. The standards specified in NICE technology appraisals (TA130, TA186, TA195, TA198, and
TA225) were used to assess compliance with NICE guidance. Descriptive statistical analysis was performed.
Results: There were 335 biologic drug switches in 317 patients. The most common reason given for switching to a
drug was NICE guidelines (242, 72.2%), followed by Physician's choice (122, 33.4%). Lack of effect was the most
common reason for discontinuing a drug (224, 67%). For patients on Rituximab, Methotrexate was used in 133
switches (76.9% of the time). Overall NICE compliance for all units was 65% (range 50 to 100%), with anti-TNFα to
anti-TNFα switches for inefficacy making up the majority of non-compliant switches.
Conclusion: This study draws attention to the enigma and disparity of commissioning and prescribing of biologic
drugs in RA. Currently the evidence would not support switching of a biologic drug for non-clinical purposes such
as economic pressures. Flexibility in prescribing should be encouraged: biologic therapy should be individualised
based on the mode of action and likely tolerability of these drugs. Further work should focus on the evidence for
using particular sequences of biologic drugs.
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Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory disease with characteristic pathological changes
of synovial hypertrophy, peripheral joint inflammation
and destruction, giving the potential for extra-articular
manifestations. Prevalence ranges from 0.5-1.5% of the
population in industrialised countries, increasing with
age and peaking between the ages of 35 and 50 years.* Correspondence: timblakewarwick@gmail.com
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unless otherwise stated.The incidence of RA is around 1.5 per 10,000 men and
3.6 per 10,000 women per year. RA is associated with
significant morbidity, including pain, disability and work
incapacity. Moreover, the disease carries a substantial fi-
nancial cost to the UK economy, estimated at between
£3.8 and £4.75 billion per year [1].
Management of RA consists of an integrated ap-
proach that includes both pharmacological and non-
pharmacological therapies. Medications include traditional
non-biologic and biologic disease-modifying anti-
rheumatic drugs (tDMARDs and bDMARDs). Over
the past two decades, there has been a major shifttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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duction of DMARDs, especially the use of biologic
agents including anti-tumour necrosis factor alpha
(anti-TNFα) agents (Adalimumab, Etanercept, Infliximab
etc.) [2-6]. Other classes of bDMARDs comprise B-Cell
depleting therapy (Rituximab), Il-6 blocking therapy
(Tocilizumab) and T-cell co-stimulatory inhibitor therapy
(Abatacept) [7-9]. The efficacy of these agents has been
validated in several randomised controlled trials and meta-
analyses [10-12]. Switching (or cycling) among biologic
therapies has been advocated where patients have shown
an inadequate response or adverse events.
The National Institute for Health and Clinical Excellence
(NICE) is a UK national health body that was established
to reduce postcode prescribing. It has issued disease spe-
cific technology appraisals (TAs) 130, 186, 195, 198 and
225, that provide clinicians with guidance on the sequential
use of biologic drugs for the treatment of RA [13-17]. In
brief, NICE recommends switching between biologic drugs
when the first agent (usually an anti-TNFα agent) is associ-
ated with an inadequate response or poor tolerability,
based on evidence derived primarily from observational
studies. Furthermore, a growing body of evidence from
randomised controlled trials indicates that the non-TNFα
biologic drugs are more effective than placebo in patients
with an inadequate response to at least one anti-TNFα
agent [7-9,18].
Biologic agents are expensive treatments when com-
pared to the traditional DMARDs used in rheumatology.
Recent economic pressures on healthcare budgets have
led to unverified reports of some patients with RA being
switched to alternative biologic drugs for non-clinical
purposes (such as patient access schemes), despite lim-
ited clinical evidence to support this practice.
The aim of this bi-regional audit was to evaluate the
extent to which rheumatology units across the Midlands
were complying with NICE guidance on the switching of
biologic drugs in RA. These units provide rheumato-
logical services to 9.9 million (94.3%) of a total popula-
tion of 10.5 million people across the Midlands. We also
analysed the various prescribing patterns of these drugs
across the region, in particular constraints in selecting
different agents, and whether switching was being influ-
enced by non-clinical factors.Methods
Study design
Twenty two units across the East and West Midlands were
invited to participate in the audit. A questionnaire was sent
to lead clinicians at each unit to gather information on the
total number of patients with RA on a biologic drug, local
restrictions on prescribing biologic drugs, use of first-line
biologic agents after failure of conventional DMARDs, andestimation of the number of patients having a 6-monthly
28-joint Disease Activity Score (DAS-28).
An audit proforma was created using the guidance
specified in NICE TA130, TA186, TA195, TA198, and
TA225, to assess compliance with biologic drug switch-
ing in RA. Data was collected on all patients switching
from one biologic agent to another during 2011 (Table 1).
Data included: age, gender, rheumatoid factor and anti-
cyclic citrillunated peptide (anti-CCP) status, sequencing
and number of switches of a biologic drug, reasons for
choosing to discontinue or start a new biologic drug,
drug survival length, use of concomitant Methotrexate
(MTX) or other DMARDs at the time of switching,
compliance with DAS-28 response criteria, and previous
biologic drugs used pre-2011. Patients starting their first
biologic agent were excluded from the audit. Some ques-
tions allowed for selecting multiple options.
Ethics
The survey was reviewed by the local Research and
Development team and was deemed not to require
Ethics Committee approval.
Audit standards
Standards were derived from the NICE commissioning
algorithm on biologic drugs in RA, that has consolidated
guidance from the five technology appraisals (TAs 130,
186, 195, 198 and 225) on the use of biologic drugs based
on efficacy, safety and cost-effectiveness.
The current standard of practice in the UK is to start
a patient on anti-TNFα therapy when they demonstrate
a DAS-28 > 5.1 on two occasions, one month apart, and
failure of two tDMARDs (one being MTX).
The decision to initiate a biologic drug should be guided
by whether the patient is taking MTX. Where MTX is co-
prescribed, NICE instructs the clinician to use the least ex-
pensive TNFα inhibitor: Adalimumab +MTX (TA 130);
Certolizumab +MTX (TA 186); Etanercept +MTX (TA
130); Golimumab +MTX (TA 225); or Infliximab +MTX
(TA 130). If a biologic drug has to be withdrawn because
of an adverse event within the first six months of treat-
ment, initiation of an alternative TNFα inhibitor may be
considered.
For patients displaying a suboptimal response to anti-
TNFα therapy (defined as a lack of improvement in
DAS-28 of 1.2 or more at six months), clinicians may
consider switching to a biologic agent in a different drug
class. At the end of 2011, the only second-line biologic
drug recommended for this purpose was Rituximab, to
be co-prescribed with MTX (TA 195).
If Rituximab has to be withdrawn because of an ad-
verse event, one may consider treatment with the follow-
ing: Abatacept +MTX (TA 195); Adalimumab +MTX
(TA 195); Etanercept +MTX (TA 195); Golimumab +MTX
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How many times did the patient switch (change) their biologic drug
in 2011?1, 2, 3, more than 3
2. Biologic drug being switched to:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab,
Infliximab, Rituximab, Tocilizumab
3. Biologic drug being switched from:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab,
Infliximab, Rituximab, Tocilizumab
4. Why was the biologic drug in 2. chosen?
Departmental protocol, risk of tuberculosis/other infection,
commissioning restriction, patient choice, research participation,
pharmaceutical incentive, physician’s choice
5. Why was the biologic drug in 3. discontinued?
End of trial, lack of effect, intolerance/adverse event, drug site
reaction, cardiac side effects, respiratory side effects, malignancy,
neuropathy, demyelination, tuberculosis, septic arthritis, other infection
6. Did the patient continue with the biologic drug in 2. for the next
six months?
Yes, no
If Yes, did the DAS-28 score meet NICE response criteria?
Yes, no, not assessed
7. Was concomitant Methotrexate used?
Yes, No
If No, what was the reason for not using?
Free text
8. Other concomitant DMARDs used at the time of the drug switch:
Azathioprine, Ciclosporin, Corticosteroids, Cyclophosphamide, Gold,
Hydroxychloroquine, Leflunomide, Penicillamine, Sulfasalazine, Other
9. Repeat steps 2. To 8. with successive switches
10. Biologic drugs used pre-2011:
Abatacept, Adalimumab, Certolizumab, Etanercept, Golilumab,
Infliximab, Rituximab, Tocilizumab
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MTX (TA 198).
Inadequate responders to Rituximab (defined as a lack
of improvement in DAS-28 of 1.2 or more at six months),
are directed to Tocilizumab, to be co-prescribed with
MTX (TA 198).
In the case of intolerance to MTX, NICE permits the
use of Adalimumab (TA 130), Etanercept (TA 130) and
Certolizumab (TA 186) as monotherapy, in accordance
with drug licenses. An alternative TNFα inhibitor in this
group may be considered, if there is an adverse event
within the first six months of treatment requiring cessa-
tion of the original biologic agent.
Data analysis
Data was collected via web-based data collection soft-
ware hosted at one of the participating audit centres
(Russells Hall Hospital, Dudley) and was subsequently
exported into Microsoft Excel Descriptive data analysis
was performed using Microsoft excel and PASW® Statis-
tics 18.Results
Eighteen of the 22 invited units participated in the audit;
each one was randomly issued with a participating number.
There were 335 biologic drug switches in a total of 317 pa-
tients across the 18 participating rheumatology units.
Forty-five percent (143/317) of patients were in the age
range of 51 to 65 (mode). Seventy-five percent (238/317) of
patients were female. Sixty-seven percent (212/317) of pa-
tients displayed seropositivity for rheumatoid factor and/or
anti-CCP antibodies. In 94% (299/317) of cases, switching
of biologic drugs occurred only once during the 12 month
study period.
Selection of biologic drugs
Of the switches, 85.7% (287/335) were from an anti-
TNFα agent: Etanercept 38.5% (129), Adalimumab
24.2% (81), Certolizumab 15.2% (51), and Infliximab
7.8% (26). 13.4% (45/335) were from Rituximab, and
0.9% (3/335) from Tocilizumab. There were no switches
from Abatacept.
One hundred and seventy three of 335 (51.6%) switches
were to Rituximab, with the majority being from an anti-
TNFα agent (99.4%, 172/173). Similarly, 29.6% (99/335)
of switches were to an anti-TNFα agent (42.4% (42)
to Etanercept, 31.3% (31) to Adalimumab, 19.2% (19) to
Certolizumab, 5.1% (5) to Infliximab and 2.0% (2) to
Golimumab. The overall sequencing of biologic drug
switches is depicted in Table 2.
The most common reason given for switching was
NICE guidelines (72.2%, 242/335), followed jointly by
Physician’s choice (33.4%, 122/335) and Departmental
Table 2 Overall sequencing of biologic drug switches
Anti-TNFα Rituximab Tocilizumab Abatacept Total
n (%) n (%) n (%) n (%) n (%)
Anti-TNFα 84 (25.1) 172 (51.3) 21 (6.3) 10 (3.0) 287 (85.7)
n (%)
Rituximab 15 (4.4) - 26 (7.8) 4 (1.2) 45 (13.4)
n (%)
Tocilizumab 0 (0) 1 (0.3) - 2 (0.6) 3 (0.9)
n (%)
Abatacept 0 (0) 0 (0) 0 (0) - 0 (0)
n (%)
Total 99 (29.6) 173 (51.6) 47 (14.0) 16 (4.8) 335 (100)
n (%)
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up 0.3% (1/335) of reasons for switching of a biologic drug.
A proportion of switches were for more than one reason.
Lack of effect was the most common reason cited for dis-
continuing a drug (67%, 224/335), followed by adverse
drug reactions (22.7%, 76/335).
Rituximab (first-line biologic) therapy
For patients on Rituximab, Methotrexate was used
76.9% (133/173) of the time, and 67.1% (116/173) of
patients who were switched to Rituximab were sero-
positive. With regards to reasons cited for not using
Methotrexate in this population, 75% (30/40) had previ-
ous intolerance to the drug, 10% (4/40) had previous in-
efficacy, 5% (2/40) had documented lung disease that
would preclude treatment, 2% (1/40) stated patient
choice, and in 8% (3/40) no reason was given. Where
Rituximab was used without Methotrexate, other
tDMARDs were used in 47.5% (19/40) (some in combin-
ation): Leflunomide 20.0% (8/40); Sulfasalazine 20.0%
(8/40); Corticosteroids 7.5% (3/40); Hydroxychloroquine
2.5% (1/40), Gold 2.5% (1/40) and Ciclosporin 2.5% (1/40).
52.5% (21/40) were switched to Rituximab without con-
comitant tDMARD usage.
Monitoring
In 76% (253/335) of switches, the drug was continued for
six months. Of these, 80% (202/253) had DAS-28 response
criteria measured at NICE recommended time points.
Compliance with NICE guidance
Referring to NICE guidance during 2011, NICE compli-
ance for all units was 65% (range 50-100%), as depicted
in Figure 1. The use of Rituximab without Methotrexate
made up the majority of non-compliant switching (34%,
40/116). This was followed by anti-TNFα to anti-TNFα
switching for inefficacy (28%, 32/116); anti-TNFα switchingto Tocilizumab prior to Rituximab (14%, 16/116); Rituxi-
mab switching to anti-TNFα in cases of inadequate re-
sponse (12%, 14/116); anti-TNFα switching to Abatacept
(9%, 10/116); and Rituximab to Abatacept (3%, 4/116).
Subsequent alteration to NICE guidance since 2011
allows anti-TNFα switching to Tocilizumab, and Abata-
cept prior to Rituximab for an adverse event. This com-
prises 46.6% of causes for failure of compliance in our
2011 data.
Figure 2 illustrates the reasons for switching among
different biologic drugs. More patients switched from
Certolizumab (29.4%, 15/51) and Infliximab (30.7%, 8/26)
due to adverse reactions. With respect to inefficacy, more
patients were switched from Rituximab (73%, 33/45) than
any other biologic drug.
Our results demonstrate disparity in prescribing pat-
terns between individual rheumatology centres, in terms
of the number of switches and percentage of patients on
a biologic drug being switched (number of switches/total
number of patients on a biologic drug × 100 per unit).
Figures 3 and 4 compare these factors against NICE
compliance for individual units.
There is a negative correlation between the number of
patients on a biologic drug and the percentage of pa-
tients having six-monthly DAS-28 assessments in each
rheumatology centre (Figure 5).
Discussion
In general, this audit, which represents over 95% of the
population of the East and West Midlands, shows that
most rheumatology centres are broadly compliant with
NICE guidance on the switching of biologic drugs in
their RA patients. As would be expected, biologic drugs
that were being switched included well-established med-
ications, which still comprise the majority of biologic
use within rheumatological practice (such as Infliximab
and Etanercept). The biologic treatments that are being
Figure 1 Overall comparison of NICE compliance for each rheumatology unit.
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peutic options, including more recently NICE endorsed
drugs, such as Tocilizumab and Abatacept. The majority
of biologic switches related to inefficacy, with less than a
quarter being related to drug related side effects/ intoler-
ance. This audit has shown that anti TNFα to anti TNFα
switching for inefficacy is one of the commonest causes
of non-compliance with NICE guidance. This finding
has some relevance when planning potential biologic
treatment flows, as having intolerance to individual ther-
apies appears to allow a wider selection of therapeutic
options with the NICE framework when compared to
inefficacy.
This audit highlights a wide variation in compliance
between individual centres with NICE guidelines on
the switching of biologic drugs in RA (between 50 andFigure 2 Reasons for switching from a biologic drug.100%). This suggests that there are major local influ-
ences on compliance. Although this could be related to
clinicians being unaware or unwilling to follow NICE
guidance, it is likely that certain rheumatology units
have local agreements that permit prescription outside
these constraints. However, with such complex and
changeable guidelines for RA treatment, it would not be
surprising to find confusion regarding best practise in
this area due to: a) conflicting national and international
guidelines [19], b) updates in NICE guidance and c)
changes in the scientific evidence base. Recent NICE
guidance, which offers a wider spectrum of first-line bio-
logic treatment options, may help this situation, al-
though the stipulation of using the ‘cheapest option’ may
have a contrary effect, restricting the potential for indivi-
dualised care.
Figure 3 Number of switches compared to NICE compliance.
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with the introduction of clinical commissioning groups
(CCGs), which has the potential to worsen inequality
and disparity between geographical areas, by the applica-
tion of complex drug pathways. The audit raises import-
ant questions about how these drugs should be
commissioned in the future, particularly with the advent of
specialist commissioning structures now taking a leading
role in advising on biologic use outside of NICE guidance
for certain rheumatological diseases (such as SLE).
The major areas of suboptimal adherence pertained to
sequencing of biologic drugs in relation to inadequate
response (which is the most likely area to be influenced
by new scientific evidence), use of Rituximab withoutFigure 4 Percentage switching compared to NICE compliance.MTX, and monitoring of therapy. We know from phase
II studies that co-administration of Rituximab and MTX
affords a better outcome [20], with only limited evidence
for co-administration of other tDMARDs. The extent to
which the benefit of MTX influences the efficacy of
newer biologic agents remains to be fully defined and is
the subject of on-going interventional studies. For the
present time, clinicians should generally aim to use these
agents in conjunction with MTX. The significant num-
ber of patients within this audit that received Rituximab
in the absence of methotrexate highlights the import-
ance of further research into this area.
There is a non-significant trend towards a negative
correlation between the number of RA patients in any
Figure 5 DAS-28 compliance compared to the total number of patients on biologic drugs.
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those having regular DAS-28 assessments. This finding
may suggest that a strain on existing resources may
adversely affect patient surveillance. This is an important
factor to consider when developing and commissioning
future rheumatology services, particularly as depart-
ments merge and biologic drug use escalates. Although
DAS-28 has its limitations, it will remain the main
biologic response assessment tool, until a validated alter-
native can be developed [21]. Local and national commis-
sioning of biologic therapy clearly needs to take into
consideration support services for drug monitoring as
well as the not so insignificant drug costs.
Currently the evidence would not support switching of
a biologic drug for non-clinical purposes. Despite signifi-
cant financial strain on the NHS, it was encouraging to
see that financially driven switches in biologic medica-
tion occur, but are extremely rare. Nevertheless, there is
likely to be a reluctance to declare pharmaceutical incen-
tives as a reason for choosing a particular biologic drug.
The prevailing limitation of this study is the fact that it
is impossible to state the overall efficacy and tolerability
of these drugs as only patients who had switched treat-
ment were included. In addition, the rheumatoid cohort
studied reflected a more diverse and heterogeneous
autoantibody profile than the standard RA population
quoted in the literature [22]. This suggests that this
cohort may not simply consist of classical rheuma-
toid arthritis patients, but may include some individ-
uals with less well-defined inflammatory arthritis. This
audit does not provide particularly useful data on side
effect profiles of individual biologic therapies, as it did
not include all patients on biologic treatment under
rheumatological care.The results of this survey, including comparative data
in an anonymised form, have been disseminated to indi-
vidual units, and presented and discussed at regional
meetings.
Further work should be done to determine the evi-
dence for using particular sequences of biologic
drugs in RA patients who are either intolerant or in-
adequate responders.Conclusion
This regional survey not only provides us with important
regional data on NICE compliance regarding switching
of biologic drug therapy in RA, but it also informs us of
the wide variance in prescribing practice of these drugs.
Using Rituximab without MTX and anti-TNFα to anti-
TNFα switching due to inefficacy were the main reasons
for non-compliance. We suggest that individual units as-
sess how well NICE guidance has been implemented
and adhered to at local level to assess the cost impact.
Use of national commissioning for all, and development
of a common but flexible biologic pathway may facilitate
smoother and more consistent funding for these drugs
in the future. Flexibility in prescribing is important, as
biologic therapy should be individualised based on the
mode of action and likely tolerability of these drugs.
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